Clinical trialNCT01399372CompletedPhase 2Interventional

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

SponsorRadiation Therapy Oncology GroupEnrollment91Chemotherapeutic Agent ToxicityCognitive/Functional EffectsLymphomaNeurotoxicityRadiation Toxicity

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill cancer cells. It is not yet know whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy in treating patients with primary central nervous system lymphoma. PURPOSE: This randomized phase II trial studies how well giving rituximab and combination chemotherapy with or without radiation therapy works in treating patients with primary central nervous system lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Antonio Omuro, MD
Yale University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Tel Aviv Sourasky Medical Center
Tel Aviv, Israel

United States

the Kirklin Clinic at Acton Road
Birmingham, Alabama, United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Arizona Oncology-Deer Valley Center
Phoenix, Arizona, United States
Saint Joseph'S Hospital and Medical Center
Phoenix, Arizona, United States
Arizona Oncology Services Foundation
Scottsdale, Arizona, United States
Fresno Cancer Center
Fresno, California, United States
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cordova, California, United States
Rohnert Park Cancer Center
Rohnert Park, California, United States
the Permanente Medical Group-Roseville Radiation Oncology
Roseville, California, United States
South Sacramento Cancer Center
Sacramento, California, United States
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, United States
Kaiser Permanente Cancer Treatment Center
South San Francisco, California, United States
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Northwestern University
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
Cadence Cancer Center in Warrenville
Warrenville, Illinois, United States
Maine Medical Center-Bramhall Campus
Portland, Maine, United States
Maine Medical Center- Scarborough Campus
Scarborough, Maine, United States
University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Nevada Cancer Research Foundation Ccop
Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Memorial Sloan Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center Commack
Commack, New York, United States
Columbia University Medical Center
New York, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
University of Rochester
Rochester, New York, United States
University of Cincinnati
Cincinnati, Ohio, United States
Case Western Reserve University
Cleveland, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
University Pointe
West Chester, Ohio, United States
Geisinger Medical Center
Danville, Pennsylvania, United States
American College of Radiology Imaging Network
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Geisinger Wyoming Valley/henry Cancer Center
Wilkes-Barre, Pennsylvania, United States

5 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cytarabine →Methotrexate →Procarbazine →Rituximab →Vincristine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2011
Primary completion: 19 Mar 2020
Completion: 20 May 2022
Last update posted: 20 Jul 2023
Registered enrollment: 91
Registry id: NCT01399372

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.